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Abstract
Background Despite the relatively high prevelance of
gastroparesis and functional dyspepsia, the aetiology
and pathophysiology of these disorders remain
incompletely understood. Similarly, the diagnostic
and treatment options for these two disorders are
relatively limited despite recent advances in our
understanding of both disorders. Purpose This man-
uscript reviews the advances in the understanding of
the epidemiology, pathophysiology, diagnosis, and
treatment of gastroparesis and functional dyspepsia
as discussed at a recent conference sponsored by the
American Gastroenterological Association (AGA)
and the American Neurogastroenterology and
Motility Society (ANMS). Particular focus is placed
on discussing unmet needs and areas for future re-
search.
Keywords functional dyspepsia, gastric emptying,
gastroparesis.
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INTRODUCTION
Gastroparesis and functional dyspepsia (FD), neuro-
muscular disorders of the stomach involving both
motor and sensory dysfunctions, are increasingly rec-
ognized as a cause of chronic abdominal symptoms in
patients and thus represent significant health care
burden. While there has been considerable progress in
understanding enteric neuromuscular dysfunctions
and gastric sensorimotor dysfunctions in these condi-
tions, our understanding of several aspects of these
disorders, in particular the underlying aetiology and
the relationship between enteric neuromuscular dys-
functions, whole organ physiology, and symptoms is
still limited. While gastroparesis and FD are generally
considered two distinct disorders, the distinction
between them is blurred by the considerable overlap
in symptoms and the recognition that delayed gastric
emptying can be seen in FD. New approaches are
therefore needed to aid in the diagnosis and treatment
of these disorders. Recent advances in the development
of newer, less-invasive diagnostic techniques offers
promise for understanding these conditions; whereas
recent insights into abnormalities at the cellular and
tissue level may lead to the identification of novel
molecular and cellular targets for therapy.
This manuscript reviews advances in the understand-
ing of the epidemiology, pathophysiology, diagnosis, and
treatment of gastroparesis and FD, and also addresses
unmet needs and proposes areas for future research. This
article was derived from the presentations at the AGA/
ANMS meeting on Gastroparesis and Functional Dys-
pepsia held in Orlando, Florida in January 2009.
EPIDEMIOLOGY AND DEFINITIONS
Gastroparesis
Gastroparesis is a syndrome characterized by delayed
gastric emptying in absence of mechanical obstruc-
tion.1 The main symptoms include postprandial full-
ness (early satiety), nausea, vomiting and bloating. The
aetiology of gastroparesis is multifactorial; the main
categories being diabetic, idiopathic and postgastric
surgical disorders. In one tertiary referral series, diabe-
tes mellitus (DM) accounted for almost one third of
cases of gastroparesis.2
The prevalence of gastroparesis is not well defined in
population-based studies, but the condition appears to
be relatively common, affecting up to 5 million
individuals in the United States. Women constitute
the majority of patients with a female : male ratio of
4 : 1 and the mean age of onset is 34 years.3 The reason
for the sex ratio imbalance remains unknown. There
does appear to be a gender difference in gastric emp-
tying with females having slower gastric emptying
than males.4
Symptoms attributable to gastroparesis are reported
by 5 to 12% of patients with diabetes in the commu-
nity. Higher rates of diabetic gastroparesis are generally
reported in academic centers possibly suggesting refer-
ral bias of more severe patients.5,6 In a general popula-
tion-based study from Olmsted County, MN, there was
no significant difference in prevalence for nausea and/or
vomiting or dyspepsia in type 1 or 2 diabetes relative to
community controls.7 However, using a combined
definition of delayed gastric emptying and symptoms,
the cumulative incidence over 10 years in community
type 1 DM was 4.8%, in type 2 DM, 1% and in controls,
0.1%.8 Increased prevelance of gastroparesis was dem-
onstrated for type 1 DM. Prevalence rates of gastroin-
testinal (GI) symptoms (rated often/very often) in
Australians with diabetes (predominantly type 2 DM)
were slightly higher than in controls.9
Gastric emptying disturbances, particularly delayed
gastric emptying, is thought to be responsible for the
upper GI symptoms in diabetic patients.10 In a Mayo
Clinic, teriary referral study of 129 patients with
diabetes and upper GI symptoms undergoing scintig-
raphy, 42% had normal, 36% delayed and 22% rapid
gastric emptying.11 There were approximately an equal
number of patients with type 1 and type 2 diabetes in
each category. Insulin use was associated with a lower
prevelance of rapid emptying compared to normal
emptying among the symptomatic diabetics. Signifi-
cant weight loss and neuropathy were risk factors for
delayed and rapid GE, respectively.
Once true gastroparesis develops with delayed gas-
tric emptying, symptoms can be severe with consider-
able morbidity and also mortality as gastroparesis can
contribute to worsening glycemic control due to erratic
and slow gastric emptying. In outpatient diabetics
(predominantly type 2 DM), upper GI symptoms were
associated with diabetic triopathy (retinopathy,
nephropathy, neuropathy).10 Self-reported poor glycemic
control was associated with increased prevalence of
upper GI symptoms. Interestingly, psychological dis-
tress is also linked to GI symptoms in diabetes
mellitus, particularly nausea and early satiety.12
Diabetic gastroparesis may impair quality of life
independently of other factors commonly associated
with impared quality of life, e.g. age, tobacco, alcohol
and type of diabetes. Typically, gastroparesis develops
after diabetes has been present for >10 years and
patients have evidence for autonomic dysfunction.
The increased mortality in patients with diabetic
H. P. Parkman et al. Neurogastroenterology and Motility
 2009 Blackwell Publishing Ltd114
gastroparesis is usually related to other organ dysfunc-
tion.13 The median time of death was 6 years (range:
1–12) and major causes of death were cardiovascular or
renal disease. In those patients who had died, the
duration of diabetes and scores for autonomic neurop-
athy, retinopathy, and oesophageal transit were greater
than in the patients who were alive. Trends for
gastroparesis-related hospitalizations in the United
States between 1995 and 2004 suggest an increase in
hospitalizations.14 Two recent papers demonstrate the
impact of gastroparesis on morbidity, increased hospi-
talizations, emergency department visits and in one
study, increased mortality.8,15 These new data on
incidence, natural history, co-morbidity and impact
of diabetic gastroparesis in patients in the United
States should increase awareness of this disease and
hopefully guide society, regulators, and pharmaceutical
and device industry to increase their efforts to help
patients with these unmet medical needs.
Much less is known about the epidemiology of
idiopathic gastroparesis. In a tertiary referral series of
patients with idiopathic gastroparesis,2 several sub-
groups were identified: 23% had a presentation consis-
tent with a viral aetiology and a small subset (8%) had
onset of symptoms after cholecystectomy (8%). From a
symptom standpoint, 48% had prominent abdominal
pain; other subgroups included patients with predomi-
nant symptoms of gastroesophageal reflux disease or FD.
Functional dyspepsia
Functional dyspepsia, a syndrome thought to originate
from the gastroduodenal region, is one of the most
prevalent functional GI disorders. When symptoms
are present in the absence of underlying organic disease
that is likely to explain the symptoms, determined by a
negative upper GI endoscopy, the patient is considered
to have FD.16 The epidemiology of uninvestigated
dyspepsia has mainly been studied using the Rome II
criteria.16 The prevalence rate is estimated to range
between 5 and 12% when strict criteria are used, but
liberal criteria may yield prevalences as high as 40%.17
The Rome III criteria for FD specify four specific
symptoms (postprandial fullness, early satiation, epi-
gastric pain, and epigastric burning) which are thought
to originate from the gastroduodenal region.18 In
addition, a subdivision into two new diagnostic cate-
gories of (i) meal-induced dyspeptic symptoms (post-
prandial distress syndrome [PDS], characterized by
postprandial fullness and early satiation) and (ii)
epigastric pain syndrome ([EPS], characterized by epi-
gastric pain and burning) was proposed.18 The Rome III
subdivision of FD was proposed based on the assump-
tion that different underlying pathophysiological
mechanisms would be present in each of the subgroups
and, by consequence, that different treatment modal-
ities would be most suitable for each subgroup: acid
suppressive therapy in EPS, and prokinetic therapy for
PDS.19 It is currently unclear whether these assump-
tions will hold up as we further understand the
aetiology of FD or whether targeted therapy will
increase therapeutic success. Recent epidemiological
studies addressed the validity of the Rome III subdivi-
sions of FD. A population-based study in Olmsted
County found support of the existence of both EPS and
PDS-like symptom groupings in the population, with
the overlap between the subgroups being less than
expected.20 On the other hand, major overlap between
EPS and PDS was found in patients referred for open
access endoscopy, and several patients with dyspeptic
symptoms were not classifiable.21 The Kalixanda study
confirmed the existence of PDS and EPS in the general
population, and provided evidence for differential
association of PDS or EPS with putative pathophysio-
logical factors, such as anxiety.22
AETIOLOGY AND PATHOGENESIS
Diabetes, neuropathy and gastroparesis
The pathophysiology of gastric motor disturbances in
diabetic gastroparesis is multifactorial including vagal
parasympathetic dysfunction, hyperglycaemia, loss of
expression of neuronal nitric oxide (nNOS), loss of
enteric neurons, smooth muscle abnormalities and
disruption of interstitial cell of Cajal (ICC) networks.
Gastrointestinal disturbances caused by autonomic
neuropathy can arise as a disabling complication of
diabetes. Between 20% and 40% of patients with
diabetes mellitus develop dysfunction of the auto-
nomic nervous system.23 Autonomic functions can be
evaluated by assessing sudomotor function (e.g., quan-
titative sudomotor axon reflex tests) and by assessing
cardiovascular autonomic reflexes including the heart
rate response to deep breathing and the blood pressure/
heart rate responses to standing or Valsalva manoeu-
vre. While patients with diabetes and gastrointestinal
dysmotility often have autonomic dysfunctions, non-
gastrointestinal autonomic dysfunctions tests do not
necessarily indicate that enteric manifestations are the
result of autonomic neuropathy.
Metabolic abnormalities such as hyperglycaemia and
electrolyte imbalances contribute to the acute disrup-
tion of GI motility in patients with diabetes. Clini-
cally, this is most apparent when diabetic ketoacidosis
occurs and the typical features of anorexia, nausea,
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vomiting, or abdominal pain develop. As the acute
metabolic derangements are controlled, GI symptoms
often resolve. Acute hyperglycaemia may cause de-
layed gastric emptying in both healthy individuals and
individuals with diabetes, even when the autonomic
nervous system is intact.24,25
Rapid gastric emptying can be seen in subgroups of
patients in the early stages of type 2 diabetes and
neuropathy-free type 1 diabetes. Normally the rate of
gastric emptying postprandially is tightly regulated, as
a result of neural and hormonal feedback triggered by
the interaction of nutrients with the upper and lower
small intestine. This feedback is caloric load-depen-
dent, relates to the length of small intestine exposed to
nutrient, and regulates the overall rate of gastric
emptying to about 2 to 3 kcal min)1. The presence of
nutrients in the small intestine is associated with
relaxation of the gastric fundus, suppression of antral
contractions, and stimulation of tonic and phasic
pyloric contractions. The main hormones involved
include cholecystokinin (CCK) from the upper small
bowel and glucagon-like peptide-1 (GLP-1), peptide YY
(PYY) from the distal small intestine, and amylin from
the pancreas.26 In addition to these hormonal feedback
mechanisms, there is neural feedback that involves
both intrinsic (the enteric nervous system) and extrin-
sic (the autonomic and central nervous systems)
components. Nitric oxide plays a role in the neural
feedback pathway.
In diabetes, there is impaired meal-induced relaxation
of the gastric fundus, increased pyloric motor activity,
fewer antral contractions, and impaired antroduodenal
coordination. Glucagon-like peptide (GLP-1) is an
enterogastrone that inhibits antral contractility and
stimulates pyloric motility both of which contributes to
inhibition of gastric emptying and reduce food intake.26
Gastroparesis and dyspepsia as hormonal
disorders
Gastroparesis is a recognized complication of a number
of endocrine disorders, particularly DM, but also
including hypopituitarism, Addisons disease, hypo-
thyroidism, hyperthyroidism and hyperparathyroid-
ism. Numerous hormones secreted by the gut and
adipose tissue, in both the fasted state (e.g. motilin,
somatostatin, ghrelin, orexin A and B, melanin con-
centrating hormone) and in response to a meal (e.g.
CCK, PYY, GLP-1, PP, oxyntomodulin, leptin, enter-
ostatin, apolipoprotein AIV, amylin) may influence
gastric motor and/or sensory function.26
In the critically ill, of whom up to 50% have
markedly delayed gastric emptying, which frequently
causes intolerance of nasogastric feedings, exaggerated
humoral inhibitory feedback on gastric emptying is
likely to be important in the aetiology of gastroparesis.
In this group, fasting and nutrient-stimulated CCK and
PYY are elevated, while fasting ghrelin is sup-
pressed.27,28 In response to duodenal nutrients, the
secretion of CCK and PYY is exaggerated, particularly
in patients with feed intolerance.28 Moreover, the rate
of gastric emptying is inversely related to both fasting
and postprandial CCK and PYY concentrations, so that
levels are higher in those patients who have feed
intolerance.28
Only a limited number of studies have investigated
the potential role of GI hormones on symptoms in FD.
In FD patients, perceptions of fullness, bloating and
nausea induced by duodenal lipid infusion are reduced
by concurrent administration of the CCK-1 receptor
antagonist, dexloxiglumide.29 There is also evidence
that the sensitivity to exogenous CCK-8 may be
increased.
Gastroparesis and functional dyspepsia as post-
infectious disorders
In contrast to the large number of prospective studies
demonstrating that IBS can follow an infectious ill-
ness,30 only two studies have addressed post-infectious
dyspepsia (PI-D). The first involved 677 cases infected
with Salmonella enteritidis through food contamina-
tion,31 new onset dyspepsia was present in 17% of
infected individuals at 3 months and 13.4% at
12 months compared with 2.6% among uninfected
controls. The risk factors for developing PI-D were
vomiting during the acute illness, the duration of pain,
and female gender. A second study of infection with
Giardia intestinalis which affected 1300 people docu-
mented 2% PI-D after infection was eradicated;32
duodenal inflammation persisted, and a subgroup of 22
patients had reduced volume to satiation and delayed
gastric emptying.33
In a cross sectional study of 400 patients with FD, 98
described an acute onset, and 66 of these were
presumed post-infectious as they had at least two of
the following; fever, myalgia, diarrhoea or vomiting.
Early satiety, weight loss and vomiting were signifi-
cantly commoner in presumed PI-D. Pathophysiology
was not significantly different in those with acute vs
non-acute onset except for a 2 fold higher prevalence
of impaired meal-related accommodation in presumed
PI-D.34
The role of common infectious agents in gastropa-
resis remains controversial. For example, Helicobacter
pylori infection in the absence of peptic ulceration is
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asymptomatic and appears unrelated to GI dysmotili-
ties.35–39 While acute Rotavirus gastroenteritis is
associated with a delay in gastric emptying,39 the
effect seems transient (<12 weeks). Similarly, healthy
adults, experimentally infected with either the Nor-
walk virus or Hawaiian virus develop gastroparesis of
unknown duration in about half the cases.40
Cross-sectional studies of gastroparesis suggests that
gastroparesis following acute infection is rare e.g.
seven of 103 cases of gastroparesis were associated
with a viral infection.41 Patients had delayed gastric
emptying or autonomic dysfunction. Although ini-
tially severe with marked weight loss, five of seven
recovered within 12 months and two showed partial
recovery. In another series of 143 patients with
idiopathic gastroparesis,42 12 cases with acute onset
showed slow resolution, four had antibodies to Cyto-
megalovirus (CMV), two to Epstein–Barr virus (EBV)
and six were not tested. Gastroparesis might represent
an autoimmune response to infection. Five individuals
have been reported developing an acute onset gastro-
paresis: three following vaccination and two after
Lyme disease.43
Future studies are required to take advantage of
modern, large scale microbial screening to determine
the contribution of infection to the aetiology of
gastroparesis and FD.
Cellular changes in gastroparesis and dyspepsia
There are very limited data on the cellular pathology of
FD. The few studies suggest increased gastric mast cell,
eosinophil degranulation and afferent dysfunction.44,45
However, the data are not robust and have not been
replicated. The limited data is most likely due the lack
of good animal models and to the need for an invasive
procedure to obtain a full thickness biopsy. Advances
in endoscopic approaches to full thickness biopsies
may enable such studies in the future.46
Considerable progress in identifying cellular defects
that underlie gastroparesis has been driven by the
availability of animal models and by the increased
availability of human tissue from the NIH-funded
gastroparesis consortium. Cellular defects in gastropa-
resis are being increasingly recognized.47 These include
loss of expression of nNOS,48–50 often not accompanied
by neuronal loss and therefore potentially reversible.51
The most common cellular defect in gastroparesis is a
disruption of ICC networks. Animal models show that
loss of ICC is associated with loss of heme oxygenase
1, resulting in increased oxidative stress.52 Re-expres-
sion of heme oxygenase results in reversal of the ICC
and normalizes gastric emptying suggesting that the
loss of ICC is due to loss of heme oxygenase and
subsequent increase in oxidative stress is central to the
development of these motor abnormalities.52 Smooth
muscle dystrophy with fibrosis can occur in severe
diabetic gastroparesis and animal models suggest this
is due to a decreased insulin and IGF-I availability with
subsequent decrease in smooth muscle steel factor
release leading to loss of ICC.53 Future studies will be
needed at the genomic and protein level to build on the
cellular findings, integrate them, and correlate the
cellular findings with whole organ physiology and
symptoms.
Visceral hypersensitivity in human dyspepsia:
from the gut to the brain
In the absence of a detectable cause for symptoms in
the GI tract, enhanced perception of physiological
signals arising from the GI tract (visceral hypersensi-
tivity) are considered a hallmark of functional GI
disorders, including FD.54 In a subset of FD patients
such hypersensitivity can be reproduced acutely by
different types of mechanical gastric distension.55,56 It
has not been possible to conclusively identify the site
and mechanisms underlying visceral hypersensitivity
in human FD patients, or to establish the translational
validity of any animal model for human symptoms.
Several functional brain imaging studies using con-
trolled gastric distension have been reported for
healthy control subjects and for patients with FD.57
Despite significant variability of results, activation of
homeostatic afferent brain circuits in FD patients has
been reported. Alterations in attentional mechanisms,
in particular an increase in threat-related attention,
associated hypervigilance and future-directed symp-
tom related fears of sensations arising from the upper
GI tract, have been suggested as important pathophys-
iological components of functional pain disorders, and
in anxiety disorders.58
In order to develop more effective therapies for
patients with gastroparesis with and without symp-
toms of dyspepsia, it is important to clearly distinguish
between patients with FD and with gastroparesis, and
to better understand the relationship between altera-
tions in gastric emptying, specific symptoms, and
altered brain responses to gastric stimuli.
Gastroparesis and functional dyspepsia – insights
from animal models
The lack of easy access of the enteric nervous system
and associated cellular elements putatively involved
in the disease process of gastroparesis and FD has
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necessitated the use of animal models to provide an
alternative means to gain insight into these syn-
dromes.47 Beginning with the seminal observation that
Nos1)/) knockout mice develop grossly enlarged stom-
achs with gastric stasis,59 much animal work in
gastroparesis has been focused on the role of this
enzyme and its key product, the gaseous neurotrans-
mitter, nitric oxide. Diabetic rodents have consistently
shown defects in nitrinergic inhibitory activity and
while most studies have examined changes in nNOS
expression, recent work has also highlighted post-
translational modifications of the enzyme including
dimerization (crucial to its activity), and protein–
protein interaction.60–63 These studies may provide
insight into the biological basis of clinical phenomena
such as the marked gender bias of gastroparesis and
identify other important molecules in the maintenance
of nitrinergic expression and function such as vagal
acetylcholine acting via nicotinic receptors, insulin
and the nNOS co-factor, tetrahydrobiopterin.60,63,64
Animal investigations have also attempted to iden-
tify the most important cellular elements involved in
gastroparesis. While enteric neuronal loss is an attrac-
tive disease mechanism, it has been difficult to dem-
onstrate this in the stomach and indeed recent human
studies suggest that this may not be in fact be a
significant component of the pathology. By contrast,
loss, or phenotypic alteration, of ICC appears to be
more important both in experimental models and the
human condition.65,66 Finally, defects in smooth
muscle function, both global and regional in nature,
have also been noted in animal models.67,68 Emerging
paradigms suggest cross-talk and linkage of the path-
ophysiological mechanisms involving these diverse but
related cellular elements.53,69
An important insight gained from animal studies has
been the role of inflammation, particularly oxidative
stress, in the pathogenesis of some of the above
abnormalities. Candidate factors promoting such in-
jury include advanced glycation end-products (AGEs)
and their receptor, RAGE.70,71 At the same time,
counter-regulatory mechanisms may be impaired, with
one example being the loss of gastric macrophage
expression of heme-oxygenase 1 (HO-1) activity.52
These findings have implications for novel therapeutic
approaches such as hemin (an inducer of HO-1) and
other forms of anti-oxidant therapies.52,72
In contrast to gastroparesis, there is a marked
paucity of true animal models of FD. Recently, a rat
model, based on the neonatal irritation paradigm, has
been described that appears to mimic both the sensory
and the motor phenomena associated with human
FD.73 It is hoped that further research with this model
may provide insight into the molecular basis of this
syndrome.
Animal models have been an important part of the
research into gastroparesis. However, while it has been
relatively simple to model diabetes (type 1 or 2) in
rodents and establish gastrointestinal dysfunction, real
breakthroughs in terms of identifying valid therapeutic
targets has been difficult to date. This is because
almost all research with animals has used motor
abnormalities (gastric emptying, intestinal transit
etc.) as the read-out. While these studies have iden-
tified key molecules (e.g. nitric oxide) or cell types (e.g.
ICC) that mediate gastric motility, little progress has
been made in the pathogenesis of the most bothersome
symptoms of these syndromes, such as nausea, vom-
iting and pain, which have been difficult to model in
rodents. This hiatus in our knowledge has been
highlighted by recent research that emphasizes the
poor correlation between gastric emptying and symp-
toms in patients. Future animal research therefore
needs to incorporate relevant measures and outcomes
in order for us to make rapid progress in the treatment
of these conditions.
DIAGNOSIS
Assessment of gastric emptying is commonly per-
formed for the evaluation of nausea, vomiting and
dyspepsia to assess for delayed gastric emptying.
Limitations of this approach include the imperfect
correlation of symptoms to rates of stomach emptying,
and the relative lack of satisfactory treatments for
abnormal gastric emptying. Nevertheless, emptying of
triturated content is arguably the most important
function of the stomach, and abnormalities associated
in either accelerated or delayed emptying may be a
marker for the underlying defect in the neuromuscular
apparatus of the stomach that gives rise to symp-
toms.74,75 Of the imaging techniques, scintigraphy is
widely available and the standard method for assessing
gastric emptying in clinical practice. However, scin-
tigraphy remains expensive and is associated with
some radiation exposure. Wireless motility capsule and
gastric emptying breath testing are newer non-invasive
technologies that allow standardization among centers
and these tests can be performed in a gastroenterology
practice. Other techniques, such as ultrasound, single-
photon emission computed tomography (SPECT) and
magnetic resonance imaging (MRI) are predominantly
research tools for evaluating gastric volumes, contrac-
tility, gastric distribution of meals, and emptying.
Tables 1 and 2 highlight strengths, limitations, and
considerations for areas of research.
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Gastric emptying scintigraphy
Scintigraphic determination of the emptying rate of a
solid meal from the stomach is regarded as the standard
measurement technique for gastric emptying. Deter-
mination of emptying rates of liquid meals is less
sensitive and generally reserved for the evaluation of
dumping syndrome and post-surgical disorders.
For solid-phase testing, most centers use a 99mTc
sulphur colloid-labelled egg sandwich as a test meal76
endorsed by a consensus statement from the ANMS and
the Society of Nuclear Medicine.77 Extending
scintigraphyto4 himprovestheaccuracyindetermining
the presence of delayed gastric emptying.78,79
Unfortunately, contrary to the evidence and consensus
recommendations, many centers in the United States
perform gastric emptying scintigraphy for merely 90 to
120 min instead of 4 h postprandially, which substan-
tially limits the clinical utility of this test.80
Regional gastric emptying can assess intragastric
meal distribution and transit from the proximal to
distal portions of the stomach and may provide greater
information regarding fundal and antral function.81
Studies have shown an association between symptoms
of nausea, early satiety, abdominal distention with
proximal gastric retention; whereas vomiting is asso-
ciated more with delayed distal gastric retention.82,83
Gastric mucosal labelling with intravenous techne-
tium-99m followed by SPECT imaging allows assess-
ment of gastric volumes. Gastric volumes, especially
impaired accommodation, are important factors in
symptom production in FD and gastroparesis. With
scintigraphy and SPECT imaging, gastric volumes and
emptying can be measured simultaneously84,85
(Table 3).
Wireless capsule motility for assessment of
gastric emptying
Wireless capsule motility uses an indigestible capsule
containing miniaturized wireless sensor technology
that measures pH, pressure and temperature as the
capsule travels through the digestive tract. Gastric
emptying is identified by the abrupt change from the
acidic pH profile of the stomach to the alkaline pH of
the duodenum. The SmartPill GI Monitoring System
(SmartPill Inc., Buffalo, NY, USA) has been approved
by the U.S. Food and Drug Administration (FDA) for
the assessment of gastric pH, gastric emptying, and
total GI transit time. Gastric emptying by the wireless
capsule correlates with the T-90% for gastric empty-
ing86 better than with the T-50% and appears to empty
with the phase III migrating motor complex signifying
completion of the postprandial phase and return to the
fasting condition.87 Using a 5 h cutoff for gastric
emptying, the capsule discriminated between normal
or delayed gastric emptying with a sensitivity of 0.87
and a specificity of 0.92. As the capsule traverses the GI
tract, the pH profile of the capsule can be used to
measure small bowel and colonic transit.88 In addition,
Table 2 Considerations for future research in gastric imaging tech-
niques
Scintigraphy Categorization of patients with discrepant
gastric emptying at 2 and 4 h, utility of
evaluating symptoms during GE,










Evaluate relationship between antral
contractility and gastric emptying
Ultrasound Extend availability to other centers
MRI Validate MRI for studying mechanical
properties, validate MRI vs manometry
for evaluating gastric contractility and
assess gastric contractility in disease.
MRI, magnetic resonance imaging; COPD, chronic obstructive
pulmonary disease.
Table 1 Comparison of methods used to assess gastric emptying
Scintigraphy Breath test Capsule
Mechanisms of gastric emptying Antral motor activity Antral motor activity Antral motor activity and
migrating motor complex activity
Validation studies Extensive Modest Modest






Limitations for testing None Malabsorption, liver failure,
pancreatic/pulmonary disease
Obstruction
Assessment of antral contractility Feasible No Yes
Assessment of small bowel and
colonic transit
Yes No Yes
CV%, percentage coefficient of variation; Inter and intra, inter- and intra-individual coefficient of variation.
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pressure measurements provide information about
motor functions of the stomach, small intestine, and
colon.89
Gastric emptying breath test
Another alternative method for assessing gastric func-
tion includes the gastric emptying breath test (GEBT)
using 13C, a stable (non-radioactive) isotope. Tests have
used either with the eight-carbon saturated fatty acid,
octanoic acid or the blue-green algae, Spirulina plat-
ensis. The 13C containing substrates empty from the
stomach, are absorbed in the small intestine, undergo
catabolism in the liver, enter the bodys bicarbonate
pool, and then are excreted as 13CO2 in the breath,
where 13C can be detected by mass spectrometry. The
rate-limiting step in this process is the stomach
emptying rate.90,91
There have been numerous studies with simulta-
neous scintigraphy and breath test validating the
breath test to measure gastric emptying. The best
validated GEBT (by numbers and spectrum of gastric
emptying disorders tested) is the shelf-stable 238 kcal
meal consisting of freeze dried egg mix, saltine crack-
ers, water and 100 mg of 13C S. platensis.92 Perfor-
mance characteristics of this test meal were 89%
sensitivity and 80% specificity in identifying delayed
gastric emptying utilizing the breath sample values at
150 and 180 min, and 93% sensitivity and 80%
specificity for identifying accelerated gastric emptying
utilizing the breath sample values at 45 and 180 min
(with scintigraphy as gold-standard). The test is not yet
approved by the FDA.
Ultrasonography: 2D and 3D
Transabdominal ultrasonography represents a rela-
tively simple, non-invasive, inexpensive technique for
the assessment of GI motor function. In the stomach,
it can assess structural and functional abnormalities.
Ultrasonography has now been used to study gastric
distension/accommodation,93,94 antral contractil-
ity,95,96 mechanical deformation (strain),97 transpyloric
flow,96 and gastric emptying.98,99 Ultrasound (US) is
uniquely suited for concurrently measuring antral
contractility, pyloric opening, pyloric flow and perhaps
gastric emptying.100,101 However, only a handful of
centers have studied gastric motility by US, which
requires considerable technical expertise.
2D ultrasound (2D-US) provides an indirect mea-
surement of gastric emptying which is determined by
quantifying changes in antral area over time.96 A probe
is placed over the abdomen and a parasagittal image of
the antrum is obtained in the region of the aorta and
superior mesenteric vein.98 2D ultrasound has been
used in studies in health and disease and validated in
comparison to scintigraphy.98 Diseases have included
FD which is frequently associated with increased
antral area (both fasting and postprandial),102 overall
delayed gastric emptying with occasionally more rapid
early emptying,103 and impaired proximal stomach
accommodation.104 In diabetes, both fasting and post-
prandial antral area are frequently increased,105 prox-
imal stomach area reduced106 and gastric emptying is
delayed in 50% of patients. 2D ultrasonography
provides a simple and straightforward assessment of
gastric emptying for clinical purposes. A limitation of
2D measurements of gastric emptying is that the
technique uses liquid meals and relies on assumptions
about the geometry of the stomach based on a single
parasagittal antral image.98 Another limitation, present
in all ultrasonographic techniques, is the inability of
imaging through air.
3D ultrasonography offers the ability to assess
intragastric meal distribution that is often disordered
in FD and gastroparesis.24 Studies using 3D ultraso-
nography have confirmed that both fasting and post-
prandial antral volumes are increased in FD.94,107
Table 3 Strengths and limitations of imaging
techniques for measuring gastric volumesTechnique Strengths Limitations
SPECT Extensively validated
Can be combined with scintigraphy to
assess gastric emptying
Radiation exposure
Limited temporal and spatial
resolution
Ultrasound No radiation
Can also assess antral contractility
and pyloric flow






Can also assess gastric air
and fluid volumes, contractility,
secretion and emptying
Expense and limited availability
SPECT, single-photon emission computed tomography; MRI, magnetic resonance imaging.
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Gastric accommodation, as assessed by changes in the
ratio of the total/proximal gastric volume, are de-
creased in FD compared to healthy subjects94,108 and
assessment of proximal gastric volumes by 3D ultra-
sonography correlates closely with measurements
made with the gastric barostat.94 While 3D ultraso-
nography provides much more information about
gastric pathophysiology than 2D ultrasonography, it
is a time-consuming technique that requires the skill
of an experienced operator and relatively expensive
equipment.
Magnetic resonance imaging assessment of GI
function
Magnetic resonance imaging (MRI) of GI function has
been used in the past by only a handful of researchers
but it is now rapidly developing and may soon be a
clinically relevant tool. Once hindered by abdominal
motion and long acquisition times, with the develop-
ment and optimization of ultra-fast echo-planar
MRI,109,110 researchers have gained the ability to
acquire images of the body in a fraction of a second,
thereby overcoming motion artifacts and moving
organs. This has allowed several aspects of GI function
to be imaged in real time. Magnetic resonance imaging
provides detailed insights on anatomy and allows
gaining complementary information about the tissues
and the composition of gut contents. Multiple param-
eters can be assessed in subjects delineating gastric
contents and measuring gastric volumes and emptying.
Gastric emptying measurements using MRI were
validated against simultaneous double marker indica-
tor technique,111,112 and gamma scintigraphy for a
liquid112,113 and mixed solid/liquid meal.113 Magnetic
resonance imaging measures gastric volumes with
acceptable performance characteristics with good
reproducibility.114,115
Magnetic resonance imaging of GI function has
recently started to be applied to the field of gastroparesis
and FD and the effects of pharmacological intervention
especially in diabetic gastroparesis. A study that
assessed 10 gastroparesis patients (who received a
400 mL high caloric pudding) found reduced antral
wave propagation speed and motility index (calculated
as a product of velocity and deepness of contraction) in
the gastroparesis group compared to 10 healthy volun-
teers.116 Intersubject and intrasubject variability in
eight FD and eight healthy controls106 showed excellent
reproducibility between days in both groups in terms of
meal volumes and gastric emptying times.
Gastric volumes measured by MRI and ultrasound
are lower and more realistic than those measured by a
barostat because the former do not distend the stom-
ach.117,118 Magnetic resonance imaging has better
temporal and spatial resolution and has been validated
but less widely used than SPECT.114 In addition to
measuring total gastric volume, MRI has the unique
ability to discriminate between gastric air and fluid,
and therefore assess gastric emptying and secretion
concurrently. Rapid MRI imaging sequences can assess
gastric contractility. Magnetic resonance imaging can
also visualize intestinal fluid and caliber.119
The advantages of functional GI MRI are high
imaging speed, high image resolution, richness of
contrast, three-dimensional coverage of the abdomen
and spectroscopic capability to provide localized infor-
mation on metabolites. Magnetic resonance imaging
can also measure other parameters of pathophysiolog-
ical interest such as intragastric distribution of food,
intragastric flow, and intragastric dilution by secretion,
and parameters reflecting gallbladder function, blood
flow to the gut.110,112 It is patient-friendly, non-
invasive and safe, thus allowing serial, dynamic stud-
ies and it can acquire many different parameters
within a single session. Patients can be asked to score
symptoms during the scans allowing direct comparison
with the MRI parameters measured. However, MRI
does has limitations. It is not suitable for patients with
metal implants or a large body frame. The study is
conducted supine, data processing is still a burden,
there is a lack of standardization, and MRI scan time is
expensive.
PATIENT MANAGEMENT
Treatment is targeted at reducing symptoms, correct-
ing fluid, electrolyte, and nutritional deficiencies along
with correcting the precipitating cause, if possible.1
Nutrition assessment and dietary treatment
There are no prospective, randomized controlled trials
comparing dietary treatments in patients with gastro-
paresis. A low fat, low fibre diet of small portions and
frequent feedings are often recommended. This is
based on studies that demonstrate fat slows emptying
in normal volunteers. Fibre is limited due to the
presumption that these patients are at risk for bezoar
formation.120,121 Smaller, frequent meals are recom-
mended as large volumes slow gastric emptying aggre-
vating the early satiety often seen. Patients are also
advised to chew foods well since the antrums grinding
capability is altered. Patients should remain upright in
an effort to use of gravity to move food from fundus to
antrum in order to decrease reflux after meals.122
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Unintentional weight loss is the most obvious
marker of nutritional compromise. Five percent loss
of usual body weight (UBW) over 3 months or 10% loss
over 6 months is indicative of severe malnutrition.123
It is important to compare the patients usual body
weight with their current actual weight. An important
consideration for this patient population when assess-
ing weight changes is hydration status, particularly
those admitted after several days of vomiting, diar-
rhoea, or in diabetic ketoacidosis. An often overlooked
patient population at high risk for gastroparesis is
chronic haemodialysis patients. Weight fluctuations
can occur in relationship to the dialysis sessions –
either hemodialyis or peritoneal dialysis.
Oral nutritient drinks are often used for dietary
supplementation. The clinician needs to be aware that
many enteral formulas on the market also contain
fructooligosaccharides which many patients may not
tolerate.
In the malnourished patient, enteral feeding options
may need to be considered for nutritional support.
Nutrition support should be considered in patients
who experience significant unintentional weight loss
of 5–10% over 3–6 months respectively, have been
unable to achieve the weight goal identified by the
healthcare team, require gastric decompression, or
have repeated hospitalizations for hydration, nutrition
medication delivery.124
Enteral feedings are given into the small intestine to
bypass the dysfunctional stomach. Although various
facilities have their favourite feeding modality (percu-
taneous endoscopic gastrostomy/jejunostomy, naso-
gastric-jejunal tube, surgical or laparoscopic
jejunostomy, or both a gastrostomy and jejunostomy),
there has yet to be a prospective controlled trial that
demonstrates superiority of one over the other. In
patients suspected as having dysmotility in the small
bowel or colon, a 48 h nasojejunal feeding trial to
determine if enteral feedings are tolerated may be
prudent prior to endoscopic or surgical placement.
Venting gastrostomies have been successful in
reducing hospitalizations for some patients.124 Some
experts refute the benefit of gastric venting asserting
that it may delay the recovery of gastric motility, but
no data exists to support this concept.
During initiation of enteral feeding, some recom-
mend strict nothing to eat (NPO) status for at least the
first 48 h. This allows separting enteral intolerance
from oral intolerance if problems with enteral infusions
develop. Formula selection should begin with a stan-
dard polymeric, non-fibre containing formulas as fibre
may cause or increase in gas, bloating and cramping. In
those patients at risk for refeeding syndrome,125 caloric
infusions are started slowly at 20 calories kg)1 until
potassium, phosphorous, and magnesium, in particular,
stabilize. Jejunal feeding is often given overnight so oral
intake can continue as tolerated during the day. If
diarrhoea occurs with enteral feeding, medications
should be reviewed, especially liquid formulations, as
they often contain sugar alcohols such as sorbitol that
may cause osmotic diarrhoea. If the diarrhoea contin-
ues, patients should be evaluated for C. difficile colitis
and small intestinal bacterial overgrowth. Once infec-
tious agents are ruled out, gut-slowing medications can
be tried. If a fibre-containing formula is used, switching
to one without fibre may prove beneficial. Other
changes in the enteral formulation have been tried to
decrease the enteral feeding-induced diarrhoea. Modi-
fying the enteral feeding regimen (e.g. dilution) may
resolve the diarrhoea which may be from the hyper-
osmolar nutrient fluid. In a subset of patients, the
infusion rate can also be reduced with an increase in the
concentration of the formula so total calories per day do
not change very much. In diabetic patients, careful
control of glucose is important for two reasons: to
maximize utilization of nutrients, and to avoid further
aggravation of gastroparesis from hyperglycaemia.126
Wide swings of glucose are especially problematic.
Total parenteral nutriton should be reserved only for
those patients who have failed an enteral feeding trial
with several formulas.
There is a paucity of prospective, randomized clin-
ical trials in the area of nutrition intervention in
patients with gastroparesis. The clinician is left using
presumptions of GI function based on trials of single
meals or nutrients in normal patients or in small
heterogeneous populations of patients with gastropa-
resis along with his or her best clinical judgment and
the patients preferences and overall goals.
Treatment
Treatment has several goals: restoration of hydration,
nutrition (enteral route being preferable), correction of
electrolyte, glycemic imbalances, reducing vomiting
with antiemetic agents, enhancing gastric emptying
with prokinetic agents, and pain relief without narcot-
ics. Recent reviews provide algorithms on the use of
treatments based on severity of symptoms, degree of
delay of gastric emptying, and ability to maintain
hydration and nutrition by oral route.127,128 Treatment
must include not only relief of symptoms, but also
restoration of nutritional status.
Initial treatment of diabetic gastroparesis should
focus on blood glucose control. Even with mildsymp-
toms, gastroparesis interferes with nutrient delivery to
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the small bowel and disrupts the relationship between
glucose absorption and exogenous insulin administra-
tion. This may result in wide swings of glucose levels
and unexpected episodes of postprandial hypoglyca-
emia. Gastroparesis should be suspected in diabetic
patients with erratic glucose control. It may, in its most
troublesome form, cause chronic nausea and anorexia,
punctuated by bouts of prolonged emesis requiring
hospitalization for dehydration and uncontrolled hyper-
glycaemia. Inexplicably, symptoms are variable and
may fluctuate markedly over a period of weeks to
months.129
Drugs with anticholinergic potential that may fur-
ther decrease gastric emptying should be reduced or
withdrawn. Of particular concern, is the increased use
in the treatment of diabetes of drugs that mimic or
modify incretins which slow gastric emptying and may
aggravate symptoms of gastroparesis. For example,
amylin delays gastric emptying. Exenatide, a mimetic
of GLP-I used in treatment of type 2 diabetes, delays
gastric emptying. In contrast, inhibitors of the enzyme
dipeptidyl peptidase 4 (DPP-4), which break down
GLP-I, do not delay gastric emptying nor reduce food
intake.130
Oral metoclopramide and domperidone are useful in
the treatment of gastroparesis.131,132 Domperidone and
metoclopramide are equally effective in reducing
symptoms of diabetic gastroparesis, particularly nausea
and vomiting. However, adverse CNS effects are more
severe and more common with metoclopramide, e.g.
somnolence and reduction in mental acuity.132 Meto-
clopramide is available intravenously and useful for
hospitalized patients. In February 2009, the FDA
announced that manufacturers of metoclopramide
must add a boxed warning to their drug labels about
the risk of its long-term or high-dose use. Chronic use
of metoclopramide has been linked to tardive dyskine-
sia, which may include involuntary and repetitive
movements of the body. Domperidone is not approved,
but it can be obtained by filing for an investigational
new drug application to the FDA and obtaining local
IRB approval. Some compounding pharmacies in the
United States provide domperidone. The maximum
dose should be no more than 20 mg QID.
Erythromycin, besides being an antibiotic, is a
motllin receptor agonist. The effect of erythromycin
in gastroparesis involves two different pathways acti-
vating motilin receptors on cholinergic neurons and
muscle. It is the most effective i.v. prokinetic agent.
Unfortunately, erythromycin is associated with tachy-
phylaxis, probably by 4 weeks of oral treatment.133
Despite some initial enthusiasm for intrapyloric
botulinum toxin injection into the pylorus,134,135 ran-
domized, controlled trials of intrapyloric botulinum
toxin type A showed little efficacy for relief of symp-
toms.136,137
Endoscopic therapy or surgical procedures are
mainly indicated for establishing venting gastrostomy
or feeding jejunostomy or for the implantation of a
gastric electrical stimulater. Feeding jejunostomy or
venting gastrostomy tubes in upper GI motility disor-
ders reduces hospitalization rate by factor of 5 during
the year after placement.124 Enterra gastric electric
stimulation is approved for humanitarian use device.
The literature documents that Enterra gastric electric
stimulation therapy leads to improvement in symp-
toms, reduced need for nutritional support documented
in open-label studies of idiopathic, diabetic and post-
surgical gastroparesis. The mechanism of symptom
relief is unclear as gastric emptying, in many patients,
is unchanged.
In some instances, near-total gastrectomy may be
helpful for severe postsurgical gastric stasis with
reduction in nausea, vomiting, and postprandial
pain.127
New experimental treatments include the following:
1 New motilides: Mitemcinal enhances gastric empty-
ing and postprandial glycemic control. The best
subgroup to use mitemcinal is unclear. Poor
responders include obese diabetic patients with poor
glucose control. Paradoxically, response rates were
higher in patients with non-delayed gastric emptying
than for those with delayed gastric emptying.138,139
2 Ghrelin and ghrelin receoptor agonists: There is
evidence that pharmacological doses of ghrelin
accelerate gastric emptying and improve symp-
toms.140,141 Contraction of proximal stomach may
conceivably aggravate postprandial symptoms.
3 5-HT4 agonists: Prucalopride and TD-5108 both
accelerate gastric emptying and have dose selectivity
for 5-HT4 receptors over hERG channel and other
receptors.142–145 Prucalopride has recently been
approved in Europe for chronic constipation. Neither
agent has been tested in gastroparesis or dyspepsia.
4 Acotiamide: Acotiamode (Z-338) is a muscarinc M1/
M2 receptor antagonist that enhances acetylcholine
release, may enhance gastric accommodation, and is
associated with improvement of dyspeptic symp-
toms.146
5 Iberogast is a herbal preparation of nine herbs.
Although more studies are needed, initial studies of
Iberogast show promise in treatment of dyspeptic
symptoms and for gastroparesis.147–149
Future treatments may include stem cell transplan-
tion, including of enteric nerves and ICCs.150 Trans-
planted neural stem cells survive in the pyloric wall of
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nNOS knockout mice, improve gastric emptying by
increasing relaxation of the pyloric muscle through
NO-dependent and neurally-mediated action.
Management of pain in gastroparesis and
functional dyspepsia
Pain often has been neglected in the management
gastroparesis. In the only publication strictly focusing
on pain in gastroparesis, the prevalence of pain [89%]
was similar to that of nausea [93%] and early satiety
[86%] and was greater than that of vomiting [68%].151
Other case series of gastroparesis report prevalence
rates of pain ranging from 46 to 71%2,152 and more than
90% of affected individuals state their pain is of
moderate to severe intensity.152 Abdominlal pain has
variable characteristics as reported by patients with
gastroparesis. Pan was characterized as crampy, burn-
ing, or vague in character and localized to the epigas-
trium in only 36% of cases.151 Meals exacerbated
symptoms in 80% but provided relief in 15% of
patients. Up to 80% of gastroparetic patients experi-
enced some pain at night.151 Using the Patient Assess-
ment of GI Symptoms [PAGI-SYM], upper abdominal
pain scores in patients with gastroparesis averaged 2.21
on a scale from 0 to 5.153 This value was similar to
conditions more classically associated with pain
including dyspepsia [2.27].
A limited number of investigations have addressed
the underlying causes of pain in gastroparesis. The
prevalence of pain has been found to be similar in
symptomatic individuals with normal emptying com-
pared to those with modest or severe degrees of gastric
retention,152,154 or in patients with impaired gastric
fundic accommodation.152 The prevalence of pain is
higher in those with heightened perception of gastric
distention vs those with normal sensation.152
To date, no investigation has targeted pain relief
in gastroparesis. Pain may be relieved through the
prokinetic effect of drugs.155 Uncontrolled series with
prokinetictreatmentsincludingcisparide, levosulpiride,
domperidone have observed decreases in pain that
closely track reductions in traditional symptoms of
gastroparesis such as nausea, vomiting, and full-
ness.155,156 Studies of the effects of gastric electrical
stimulation on pain in gastroparesis have yielded con-
flicting results.157–159 Other medication classes for
treatment of pain including tricyclic and tetracyclic
antidepressants and pain modulators such as gabapentin
and pregabalin exhibit beneficial effects in reducing
chronic abdominal pain of varied etiologies, but their
effects on gastroparesis pain are unknown. These agents
can also help improve nausea and vomiting. Investiga-
tions focusing on the specific effects of these and other
treatment modalities on pain in gastroparesis are war-
ranted.
Multiple mechanisms may be involved in the path-
ogenesis of visceral pain. A drug that selectively targets
a specific mechanism may not be able to resolve pain
alone. Severe visceral pain in gastroparesis may need to
be managed in a multidisciplinary approach. Various
approaches are available160,161 including the following:
(i) targeting coexistent dysmotility problems; (ii) tar-
geting inflammatory response; (iii) targeting peripheral
receptors and neuromodulators; (iv) targeting central
circuits; (v) targeting somatic hypervigilance and
related conditions; and (vi) targeting of all of the above.
Table 4 provides a summary of the characteristics of
some commonly used agents.
Careful use of opiates may need to be considered for
treatment of pain in selected cases. The weak opiate
agonist tramadol, which can also affect serotonin and
norepinephrine reuptake, appears to be a reasonable
first choice. The new kappa agonist asimadoline may
become a good choice in this group of medications.162
Antiepileptic agents have not been widely used in
visceral pain, except for the gabapentinoids. Although
each agent has different mechanisms of action, they all
have some common features which include: sodium
channel blockade, inhibition of glutamatergic trans-
mission and increasing gamma-aminobutyric acid
concentration. These agents have much less effect on
GI motility and could be very valuable therapeutic
options.
Acupuncture and biofeedback can also be very
helpful in these conditions, and with few side
effects.163,164 Possible future directions include the
increased use of ketamine, dorsal cord stimulators and
repetitive transcranial magnetic stimulation.165
Gastric electrical stimulation therapy
Gastric pacing uses high energy/low frequency to
stimulate gastric slow waves at a frequency just above
the intrinsic gastric slow wave frequency using a long
pulse duration (300 milliseconds) system. Gastric
pacing presently requires using external pulse genera-
tors due to the amount of energy required.166
The clinical use of gastric electric stimulation (GES)
as a possible treatment option for patients with gastro-
paresis was based on the experimental work performed
by Familoni et al in the 1990s in animals and
humans.167 These studies showed that electrical
stimulation with a higher frequency than the intrin-
sic gastric slow wave frequency (3 cycles per min in
humans) and shorter pulse duration (300 microseconds)
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improved nausea and vomiting, and also enhanced
gastric emptying. However, these observations have
not been confirmed or reproduced.
To date only one double-blind study (WAVESS study)
evaluated the efficacy of the high frequency/low energy
GES in patients with gastroparesis.157 Parameters used
in this study were stimulation frequency of 12 cycles
per min, with 0.1 s on and 5 s off and trains of 14 Hz
pulse frequencies with 5 mA strength. This study
included 33 patients (17 diabetic and 16 idiopathic)
who were initially subjected to 1 month each of
stimulation (ON phase) or sham stimulation (OFF
phase) in a double blinded phase of the study. Gastric
electric stimulation achieved a significant reduction in
weekly vomiting frequency and the majority patients
preferred the ON month. In the next 12 months, 80%
of patients reported a >50% improvement in vomiting
and quality of life. While the majority of patients had
improvement in gastric emptying, it still had not
returned to normal. Based on the results of this study,
the FDA approved this Enterra gastric electric stimu-
lation therapy under the Humanitarian Device Exemp-
tion in April 2000 for patients with diabetic and
idiopathic gastroparesis as a Human Use Device.
Currently in the US, over 3500 devices have been
placed over the last 9 years.
Apart from this double-blind trial, all of the pub-
lished literature on the efficacy of GES consists of
open-label studies mainly from centers with substan-
tial experience with this device. Follow-up data has
been reported for periods of up to years after implanting
the device which show improvement in symptoms
over many years.166,168,169 Early improvement in
symptoms in the first 3–6 months after placement of
the device predicts a long term control of symptoms
over many years. This open-label experience suggests
that GES also improves quality of life, reduces require-
ment for health care utilization, improves glycemic
control in diabetics, reduces dependence on enteral or
parenteral nutrition and also improves nutritional
status. A recent double-blind trial with GES in diabetic
gastroparesis has been completed: GES produced a
relatively rapid decrease in gastroparetic symptoms
initially but the subsequent double blind crossover
phase showed that GES ON was not significantly
better than OFF.170 The mechanism of action of GES is
an area of research that requires more attention.
Some of the complications related to GES placement
include intestinal obstruction from the intraabdominal
stimulating wires, infection of the pulse generator
pocket site, pain, erosion of the pulse generator through
the abdominal wall, and rarely detachment and/or
displacement of the electrodes with possible penetra-
tion of the leads through the stomach wall into the
lumen. About 5% of the devices have had to be removed
due to these complications over a 5–10 year followup.
Alternative approaches are being explored and con-
stitute exciting refinements that need to be fully
validated:
1 Long-pulse and high-energy stimulation with phys-
iological frequencies (3 cycles per min) to achieve
gastric pacing. In this method, the electrical stimu-
lus is composed of repetitive single pulses with a
pulse width in the order of milliseconds (10–600 ms),
and a stimulation frequency in the vicinity of the
physiological frequency of the gastric slow wave.
2 Single-channel GES with a pair of electrodes located
in the mid-body of the stomach and using long
pulses. This method is able to normalize gastric
dysryhthmia and may improve gastric emptying in
both patients with gastroparesis and animal models
of gastroparesis.
3 Two or four-channel GES with long pulses has been
investigated and the preliminary results from several
studies in both healthy and diseased canine models
are promising. The results in patients with severe
diabetic gastroparesis indicated that two-channel
gastric pacing at 1.1 times the intrinsic frequency
(pulse width: 10 to 300 ms and pulse amplitude: 0.5
to 3 mA) entrained gastric slow waves and normal-
ized gastric dysrhythmia.171 After 6 weeks of GES,
tachygastria was decreased, mean total symptom
score was reduced and mean 4-h gastric retention
improved.




NE 5-HT DA H1 Acetylcholine-Muscarinic Alpha 1-adrenergic 5-HT 2 and 3
Amitriptyline ++ ++++ +/) +++++ ++++ +++ 0
Desipramine ++++ ++ +/) ++ ++ ++ 0
Venlafaxine ++ ++++ +/) +/) + 0 0
Duloxetine ++++ +++++ + +/) +/) +/) 0
Mirtazapine +++ +++ 0 ++++ ++ ++ +++
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4 Temporary GES can be performed with endoscopic
placed stimulating wires or via a percutaneous
approach. Temporary GES placed with upper endos-
copy, has recently been developed. In a recent FDA
IDE trial, 58 patients were randomized into the OFF/
ON and ON/OFF groups.172 Symptom improvement
was rapid when the stimulator was ON and persisted
even after the stimulator was turned OFF in the
second half of the study. Improvement in gastric
emptying was greater with permanent compared
with temporary GES.173 Endoscopic mucosal EGG
may predict who will respond to GES, and may help
assess baseline neuromuscular status and predict
response to permanent GES. Based on temporary
GES, predictors of improvement in vomiting score
after permanent GES include: younger patient age,
higher baseline vomiting score and lower ratio
of frequency to amplitude of mucosal EGG.174
Endoscopic temporary GES may be a useful screen-
ing tool to select patients likely to respond to
permanent stimulation and to individulalize stimu-
lus parameters. Cross over device trials can be a
problem as enteric remodelling occurs rapidly. Gas-
tric electric stimulation may also be applicable to
other non-gastroparetic disorders with nausea and
vomiting.
FUTURE TRENDS IN RESEARCH AND
PATIENT CARE
The NIH gastroparesis consortium
The NIDDK Gastroparesis Clinical Research Consor-
tium (GpCRC) is a unique network of six clinical
centers and one Data Coordinating Center (DCC)
that are geared to further advance the understanding
and management of gastroparesis. The Gastroparesis
Clinical Research Consortium works cooperatively to
conduct clinical research to elucidate the pathophys-
iology and develop better treatments for gastropare-
sis. The Gastroparesis Registry is the largest, well-
characterized cohort of patients with gastroparesis
with approximately 500 patients whom will be
followed longitudinally. Treatment trials are also
underway for idiopathic gastroparesis and diabetic
gastroparesis.
The national commission on digestive diseases
The recent National Commission on Digestive Dis-
eases report includes recommendations on future
research for Digestive Diseases. The chapter on
Functional Gastrointestinal Disorders and Motility
Disorders presents relevent research goals to gastric
motility disorders which include understanding the
molecular and cellular events, the components and
functional interactions of the peripheral (autonomic
and enteric) and central nervous systems, peripheral
and central pain and sensory pathways, noxious
visceral signalling and the bi-directional brain-gut
interactions; the factors in diabetes that lead to the
development of GI and motility diseases and devel-
oping new technologies and therapeutic approaches to
effectively treat patients with functional GI and
motility disorders.
Clinical trials in gastroparesis
Entry criteria for gastroparesis trials generally depend on
gastric emptying and symptoms. Often there is a
minimum level of symptom severity for entry. Gastric
emptying tests are generally used in clinical trials for
gastroparesis to determine eligibility criteria for patients
to enter the study. Generally any delay in gastric
emptying, which defines gastroparesis, is used. Using
moderate to severe gastric emptying may allow better
correlation of symptoms to gastric emptying but may
cause difficulty in recruitment of these patients. The
gastric emptying test result at enrolment could also
serve as a covariate in analysis of symptom response to
treatment.
The Gastroparesis Cardinal Symptom Index (GCSI)
was developed as a patient reported outcome (PRO)
measure of gastroparetic symptoms and was based on
patient interviews, clinician recommendations and
medical literature.175,176 The GCSI contains nine
symptoms covering three areas: nausea/vomiting
(three items); bloating (two items); fullness/early
satiety (four items). The response scale is based on
the symptom severity over the prior two weeks with
responses from none (0) to very severe (5). The
total score is the average of 3 subscale scores and
ranges from 0 to 5. The GCSI has been used in
treatment trials: gastric electric stimulation; botu-
linum toxin injection into the pylorus; and trials
with prokinetic and antiemetic agents. For respon-
siveness to treatment of the GCSI, often a decrease
in 0.5 is used.
To minimize patient recall effects using a two week
symptom period, a GCSI daily diary (GCSI-DD) was
developed.177 Qualitative interviews in patients with
gastroparesis confirmed that the symptoms addressed
in the GCSI are the main symptoms relevant to
patients with gastroparesis. The daily diary form of
the GCSI captures daily variability of those symp-
toms, and has psychometric properties consistent
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with a good PRO endpoint for gastroparesis clinical
trials.
There is an overlap of the symptoms in patients with
FD and patients with idiopathic gastroparesis. Gener-
ally, patients with FD have more abdominal pain
whereas patients with idiopathic gastroparesis have
more nausea and vomiting. The symptoms in the GCSI
do not include abdominal pain, which would be more
suggestive of FD.
Some have suggested the gastric emptying test also
be performed during a treatment trial with the
patient on treatment at the end of the study. This
result often serves as a secondary endpoint. Further
studies are needed to address whether a composite
endpoint using both symptoms and gastric emptying
provides additional value to assess patient outcomes
in trials.
Areas that need to be explored in future studies
include:
Understanding differences between the spectrum of
symptoms in idiopathic and diabetic gastroparesis
patients.
Appreciation that within the FD patient population
up to 40% may have slow gastric emptying and
therefore qualify for the term idiopathic gastroparesis.
Differentiation between FD with delayed gastric emp-
tying and idiopathic gastroparesis may be difficult and
may need to be explored.
The validity of gastric emptying measurement in
the enhancement of clinical trials assessing symp-
toms in gastroparesis: eligibility criterion, covariate,
secondary endpoint or as part of a composite end-
point with GCSI daily diary or other symptom
instrument.
The identification of the predominant or most
bothersome symptom as a primary or secondary end-
point in treatment trials of gastroparesis.
Stem cells and regenerative medicine as a
therapeutic option
Although cell loss affecting the enteric nervous sys-
tem, ICC and smooth muscle cells occurs in several GI
neuromuscular disorders including diabetic and idio-
pathic gastroparesis,53,178–181 current therapeutic strat-
egies do not specifically target the cellular deficit.
Recent advances in regenerative medicine promise to
open new avenues for restoring tissue integrity in these
disorders.
Stem cells (SC) can be defined functionally as
uncommitted cells capable of asymmetric cell divi-
sions resulting in daughter cells identical to their
mother (self-renewal) and progeny that, through a
series of increasingly more committed progenitors,
culminate in terminally differentiated cells.182 The
differentiation potential of SC is closely related to their
developmental state. Differentiated cells can be exper-
imentally reprogrammed into pluripotent SC and thus,
theoretically, an infinite source of patient-specific
replacement cells could be created.182
The goal of regenerative medicine is to exploit SC for
tissue repair or replacement. Besides restoration of
tissue function by integration, SC can be used for the
engineering of complex tissues/organs or as vehicles to
deliver trophic, immunoregulatory, anti-inflammatory
or angiogenic signals, and genetic material.183,184
Endogenous SC could also be activated by pharmaco-
logical treatment to improve tissue function.184 Key
cell types of the GI muscle layers differ considerably in
their ability to regenerate and may require different
therapeutic strategies for repopulation. For example,
ICC have considerable regenerative capacity and thus
their networks could potentially be regenerated by
pharmacological stimulation of their local progenitors
recently identified in postnatal murine gastric mus-
cles.185 In contrast, regeneration of enteric neurons is
markedly limited and thus likely requires exogenous
sources of replacement cells such as gut-derived neural
crest SC,186 neural SC derived from the fetal central
nervous system,187 or gut-like structures obtained from
embryonic SC.188
Stem cell-based therapies promise to treat the root
cause of degenerative and congenital GI neuromus-
cular disorders. Pioneering studies have laid the
foundations for future progress. However, for the
ultimate goal to be realized, the focus of research
should shift from purely observational to mechanistic
studies.
SUMMARY
This review from the AGA/ANMS meeting on gast-
roparesis and functional dyspepsia has covered salient
aspects in the present understanding of the epidemi-
ology, pathophysiology, diagnosis, and treatment of
gastroparesis and FD. In addition, this review has
discussed unmet needs and some directions for future
research are suggested. These disorders, gastroparesis
and FD, are areas of active investigation because they
are common, the current therapy is suboptimal, and
existing treatments have not been well studied. A
combination of approaches, i.e., basic research, clin-
ical investigation, and controlled clinical trials will
likely be needed to consolidate recent advances and to
impove management of patients with these condi-
tions.
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